Clinical studiesClinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase)☆
References (53)
Laboratory manifestations of polymyositis/dermatomyositis
Clin Dermatol
(1988)- et al.
An enzyme-linked immunosorbent assay for the detection and quantitation of anti-Jo-1 antibody in human serum
J Immunol Methods
(1987) - et al.
Polymyositis and interstitial lung disease in a patient with anti-Jo-1 prototype
Am J Med
(1984) - et al.
Autoantibodies specific for U1 RNA and initiator methionine tRNA
J Biol Chem
(1986) - et al.
Fibrosing alveolitis in polymyositis
Am J Med
(1974) - et al.
Dermatomyositis and rapidly progressive fibrosing alveolitis
Thorax
(1983) - et al.
Interstitial lung disease in polymyositis and dermatomyositis
J Rheumatol
(1980) - et al.
Interstitial lung disease in dermatomyositis: clinicopathological study
J Rheumatol
(1987) - et al.
Improved detection of anti-Jo-1 antibody, a marker for myositis, using purified histidyl-tRNA synthetase
J Immunol Methods
(1987) - et al.
Response to methotrexate in fibrosing alveolitis associated with connective tissue disease
Thorax
(1980)
Immunological aspects
Higher eukaryotic aminoacyl-tRNA synthetases in physiologic and pathologic states
Mol Cell Biochem
Jo-1 and other myositis autoantibodies
Measurement of antibody to Jo-1 by ELISA and comparison to enzyme inhibitory activity
J Immunol
Cellular protein and RNA antigens in autoimmune disease
Mol Biol Med
Antibody to threonyl-transfer RNA synthetase in myositis sera
Arthritis Rheum
Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity
Nature
Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody
J Exp Med
Autoantibodies against alanyl-tRNA synthetase and tRNAala coexist and are associated with myositis
J Exp Med
Heterogeneity of precipitating antibodies in polymyositis
The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue disease
Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease
Br Med J
Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease
J Rheumatol
The Jo-1 antibody system in myositis: relationships to clinical features and HLA
J Rheumatol
Serologic and restriction enzyme studies of HLA-D region genes in myositis
Arthritis Rheum
Cited by (116)
Joint and muscle inflammatory disease: A scoping review of the published evidence
2023, Seminars in Arthritis and RheumatismPulmonary histopathology of interstitial lung disease associated with antisynthetase antibodies
2022, Respiratory MedicineA 65-year-old Woman With Persistent Dyspnea, Arthritis, and Raynaud's Phenomenon
2021, American Journal of the Medical SciencesAutoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies
2020, Journal of Translational AutoimmunityCitation Excerpt :Nevertheless, some patients appear to have idiopathic ILD for years and may not develop myositis. Reports on anti-PL-12 and anti-KS suggested that they are common in ILD without myositis [35–37], as reported also by Kalluri and Colleagues who analyzed the clinical features of 31 anti-PL-12-positive patients and reported that this autoAb is strongly associated with ILD (3/31 cases were idiopathic ILD) but less with myositis and arthritis [38], consistent with an earlier study [35,37]. Marie et al. analyzed 75 anti-Jo-1-positive patients and 20 anti-PL-7 (n = 15)/PL-12-positive (n = 5) patients and reported that the latter had milder muscle involvement, less recurrence of muscle disease and anti-PL-7/PL-12 was associated with early and severe ILD and gastrointestinal manifestations [39,40].
Pulmonary manifestations of antisynthetase syndrome
2015, Revue des Maladies RespiratoiresGene-Gene and Gene-Environment Interactions in Defining Risk and Spectrum of Phenotypes in Idiopathic Inflammatory Myopathies
2014, Between the Lines of Genetic Code: Genetic Interactions in Understanding Disease and Complex Phenotypes
- ☆
This work was supported by Grants AR-32214 and AI-27181 from the National Institutes of Health, by Veterans Administration medical research funds from the Veterans Administration Medical Center, Oklahoma City, Oklahoma, and by grants from the Arthritis Foundation.